Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 18, 2025Frontiers in ImmunologyOpen Access

Ruxolitinib and decitabine plus a busulfan–cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYujun WeiSLSonghua LuanLWLu Wang

Discussion

Loading...

Member takes

Overview

Investigational treatment reduces relapse in high-risk AML/MDS patients post-transplantation, suggesting efficacy of Rux-Dec-mBu/Cy.

Key Points

  • The 2-year cumulative incidence of relapse was 19.0%, highlighting significant maintenance of remission.
  • Patients achieved a 70.3% 2-year overall survival and 70.6% disease-free survival with the new regimen.
  • This was a prospective study involving 58 high-risk AML/MDS patients from May 2020 to July 2023, confirming treatment feasibility.
  • Adverse events included a 44.1% rate of grade II-IV acute graft-versus-host disease, indicating manageable side effects.

Cite This Study

Wei et al. (2025) studied this question.

synapsesocial.com/papers/68af31e3cf1dd9ea359e7bb8https://doi.org/10.3389/fimmu.2025.1586512
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ruxolitinib combined with decitabine-intensified modified busulfan/cyclophosphamide conditioning regimen reduces relapse after allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia2025
  2. 2An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation2025
  3. 3Phase II Study of Peri- and Post-Transplant Ruxolitinib for Patients With Myelofibrosis Receiving Allogeneic Hematopoietic Cell Transplantation2025 · 6 citations
  4. 4Prospective clinical study on the efficacy and safety of the DCIA±X regimen in treating relapsed/refractory acute myeloid leukemia2025
  5. 5Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial2025